Search
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe.
Categories: Heterocyclic Compounds, 1-RingIMA901
go.drugbank.com/drugs/DB06628InvestigationalIMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis … Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InducersProducts: CRESEMBA ® CAPSULAS, CRESEMBA® 200 MG POLVO LIOFILIZADO ESTERIL PARA RECONSTITUIRQuarfloxin
go.drugbank.com/drugs/DB06638InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBevasiranib
go.drugbank.com/drugs/DB06642InvestigationalBevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).
Categories: Compounds used in a research, industrial, or household settingSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Cytochrome P-450 Substrates, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesGMK
go.drugbank.com/drugs/DB06661ExperimentalGMK vaccine (a ganglioside conjugate vaccine coupled to keyhole limpet hemocyanin and formulated with the adjuvant QS-21) for the potential treatment of melanoma
Pasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalPasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSynonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)